A phase 1b dose-escalation study of TRC105 (endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Choueiri, T. [1 ]
Michaelson, M. D. [2 ]
Posadas, E. [3 ]
Sonpavde, G. [4 ]
McDermott, D. [5 ]
Seon, B. [6 ]
Jivani, M. [7 ]
Shazer, R. [7 ]
Adams, B. [7 ]
Theuer, C. [7 ]
机构：
[1] Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Med Oncol, Boston, MA 02114 USA
[3] Cedars Sinai Med Ctr, Urol Oncol Program, Los Angeles, CA 90048 USA
[4] Univ Alabama Birmingham Hosp, Med Oncol, Birmingham, LA USA
[5] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA
[6] Roswell Pk Canc Inst, Immunol, Buffalo, NY 14263 USA
[7] TRACON Pharmaceut Inc, Clin Operat, San Diego, CA USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw373.32
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
804P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase 1b dose-escalation study of TRC105 (anti-Endoglin Antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC)
    Choueiri, T. K.
    Michaelson, M. D.
    Posadas, E. M.
    Sonpavde, G. P.
    Mcdermott, D. F.
    Sean, B. K.
    Jivani, M. A.
    Adams, B. J.
    Theuer, C. P.
    BJU INTERNATIONAL, 2015, 116 : 4 - 5
  • [2] A phase 1b dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC)
    Choueiri, Toni K.
    Posadas, Edwin M.
    Sonpavde, Guru
    Figlin, Robert A.
    Walsh, Meghara K.
    Wall, Kevin C.
    Seon, Ben K.
    Jivani, Manoi A.
    Adams, Bonne J.
    Theuer, Charles P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma.
    Choueiri, Toni K.
    Michaelson, M. Dror
    Posadas, Edwin M.
    Sonpavde, Guru
    McDermott, David F.
    Walsh, Meghara K.
    Wall, Kevin C.
    Seon, Ben K.
    Jivani, Manoj A.
    Adams, Bonne J.
    Theuer, Charles P.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [4] An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma
    Choueiri, Toni K.
    Michaelson, M. Dror
    Posadas, Edwin M.
    Sonpavde, Guru P.
    McDermott, David F.
    Nixon, Andrew B.
    Liu, Yingmiao
    Yuan, Zhenhua
    Seon, Ben K.
    Walsh, Meghara
    Jivani, Manoj A.
    Adams, Bonne J.
    Theuer, Charles P.
    ONCOLOGIST, 2019, 24 (02): : 202 - 210
  • [5] A Phase 1b Dose-Escalation Study of TRC105 in Combination with Nivolumab in Patients with Metastatic Non-Small Cell Lung Cancer
    Robert, F.
    Theuer, C.
    Saleh, M.
    Keef, J.
    Jerome, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1976 - S1976
  • [6] TRAXAR study: a randomized phase 2 trial of axitinib and TRC105 versus axitinib alone in patients with advanced or metastatic renal cell carcinoma (mRCC)
    Choueiri, T.
    Agarwal, N.
    Ho, T.
    Pal, S. K.
    Seon, B.
    Jivani, M.
    Adams, B.
    Shazer, R.
    Theuer, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] TRAXAR study: a randomized phase 2 trial of axitinib and TRC105 versus AXitinib alone in patients with advanced or metastatic renal cell carcinoma (mRCC)
    Choueiri, Toni K.
    Agarwal, Neeraj
    Ho, Thai H.
    Pachynski, Russell
    Pal, Sumanta
    Ryan, Christopher W.
    Vaena, Daniel
    Lara, Primo
    Lawler, William
    Posadas, Edwin
    Sonpavde, Guru P.
    Wang, Peng
    Gabrail, Nashat
    Hammers, Hans-Joerg
    Merchan, Jaime
    Olencki, Thomas
    Redman, Bruce
    Sean, Ben K.
    Adams, Bonne J.
    Theuer, Charles P.
    BJU INTERNATIONAL, 2015, 116 : 5 - 6
  • [8] A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS)
    Attia, Steven
    Riedel, Richard F.
    Robinson, Steven Ian
    Conry, Robert Martin
    Sankhala, Kamalesh Kumar
    Seon, Ben K.
    Alvarez, Delia
    Adams, Bonne J.
    Theuer, Charles P.
    Maki, Robert G.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with bevacizumab (BEV) for advanced solid tumors.
    Rosen, Lee S.
    Robert, Francisco
    Matei, Daniela
    Goldman, Jonathan Wade
    Mendelson, David S.
    Chiorean, E. Gabriela
    Strother, Robert Matthew
    Seon, Ben K.
    Alvarez, Delia
    Adams, Bonne J.
    Theuer, Charles P.
    Gordon, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer
    Gordon, Michael S.
    Robert, Francisco
    Matei, Daniela
    Mendelson, David S.
    Goldman, Jonathan W.
    Chiorean, E. Gabriela
    Strother, Robert M.
    Seon, Ben K.
    Figg, William D.
    Peer, Cody J.
    Alvarez, Delia
    Adams, Bonne J.
    Theuer, Charles P.
    Rosen, Lee S.
    CLINICAL CANCER RESEARCH, 2014, 20 (23) : 5918 - 5926
12345